Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trefoil factor 3 (TFF3) is a small, highly stable secreted peptide (about 59 amino acids, 7–9 kDa) characterized by a conserved trefoil domain with multiple disulfide bonds[1][2]. It is predominantly produced by goblet cells in the gastrointestinal tract, and co-secreted with mucins to maintain epithelial integrity, reduce permeability, stimulate migration and restitution after injury, and suppress inflammation[1][4][6]. TFF3 achieves these effects partly through binding mucins and specific receptors—CXCR4, CXCR7, and PAR-2—activating key signaling pathways for cell migration, wound healing, and immune defense[3][2][1]. While essential for mucosal homeostasis, TFF3 is increasingly implicated in cancer progression, poor prognosis, metabolic disorders, and emerging roles in neuroendocrine regulation[3][5][1].
Mucosal protection and restitution via interaction with mucins and enhancement of barrier function; Activation of cell migration and healing via binding to CXCR4, CXCR7, PAR-2, and LINGO2-EGFR signaling complexes; Suppression and modulation of inflammatory pathways (e.g., MAPK, NF-κB, STAT3, PI3K, mTOR, HIF-1α)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trefoil factor 3 (TFF3).